Five countries, one regulator.

Lead Story

Definium's Phase 3 in generalised anxiety disorder read out positive on Monday. 5.1 points of placebo adjusted separation on the trial's anxiety scale at week 12, p<0.0001, no drug related serious adverse events. Definium calls it the first positive Phase 3 for a classical psychedelic in the condition.

The trial recruited in the Czech Republic, France, Germany, Poland and the UK, plus the US. The results filing names one regulator: an FDA meeting in the fourth quarter, a US approval filing in the first half of 2027.

Europe view

Panorama, NCT06809595

Country	Trials	Which
Czechia	Trials1	WhichPanorama, DT120 100 µg against 50 µg and placebo, generalised anxiety disorder, Phase 3. Definium Therapeutics US, Inc.
France	Trials1	WhichPanorama, as above.
Germany	Trials1	WhichPanorama, as above.
Poland	Trials1	WhichPanorama, as above.
United Kingdom	Trials1	WhichPanorama, as above.
United States	Trials1	WhichPanorama, as above. Not shaded: the only jurisdiction the results filing names.

Where Panorama recruited. The filing names the FDA.

Everyone is reading this as proof the drug works. We read the site list against the regulatory plan. Five European countries supplied the patients, and nothing in the filing says where they get the drug.

We called this readout in Issue 4, on 30 June. Scored today: hit. Full scoring in the ledger below.

The numbers. HAM-A (the clinician rated Hamilton anxiety scale, 0 to 56) fell 9.8 points on 100 µg against 4.7 on placebo, 96 and 97 patients respectively. Placebo adjusted means the drug arm's fall minus the placebo arm's fall: 5.1 points more improvement on drug, effect size 0.64. The 50 µg arm, 52 patients, fell 3.6, less than placebo.

Comparison

Voyage and Panorama, HAM-A at week 12

Field	Voyage	Panorama
DT120 100 µg, HAM-A change	DT120 100 µg, HAM-A changeVoyage11.6	DT120 100 µg, HAM-A changePanorama9.8
Placebo	PlaceboVoyage6.2	PlaceboPanorama4.7
Placebo adjusted	Placebo adjustedVoyage5.4	Placebo adjustedPanorama5.1
Effect size (d)	Effect size (d)Voyage0.81	Effect size (d)Panorama0.64
Patients, drug / placebo	Patients, drug / placeboVoyage107 / 107	Patients, drug / placeboPanorama96 / 97
Unblinding control arm	Unblinding control armVoyagenone	Unblinding control armPanorama50 µg, n=52

The email's table. Placebo adjusted is the drug arm's fall minus the placebo arm's fall, and it is the metric the Issue 4 call was pinned to in Issue 10; the marked cell is the one the call scored on. Voyage: two arms, US only, NCT06741228. Panorama: three arms, CZ, FR, DE, PL, UK and US, NCT06809595.

What the filing shows is a disclosed US priority. Our read, and it is an opinion, goes further: this is a decision, not an omission. A company that recruits in five European countries and names one regulator has told you its market. The US offers one approval and one scheduling decision. Europe offers one approval, then a scheduling decision and a payer negotiation in every country you want to sell in. On the economics it is hard to argue. What changes our mind is an EMA scientific advice, a European confirmatory trial or an MAA in a filing. Not a press quote.

---

Lilly closed. No 8-K.

The AtaiBeckley acquisition closed on 11 September. $6.75 in cash per share plus one contingent value right worth up to $2.50 (a CVR pays out only if a milestone hits). Every director and officer resigned. Form 25 filed to delist, Form 15 to follow.

The milestones, restated at close: VLS-01 Phase 3 initiation within four years, US approval plus DEA rescheduling of BPL-003 within five, the same for VLS-01 within seven. Three milestones, one jurisdiction. Nothing moved since we read the term sheet in July.

Lilly announced the close in a press release. Its EDGAR record shows no 8-K on it, and none was required: at Lilly's size the deal sits below the SEC's significance thresholds that make a completed acquisition reportable. Lilly's only September filing is a Form 4 for an unrelated 2025 transaction. The largest acquisition in the history of psychedelic medicine is, to its buyer, below the line where it has to be reported. The European rights came with it, and the CVR prices them at zero.

---

Deal tape

Stockholder vote, 8 September: 237.8m shares for, 5.0m against, 0.6m abstained. About 66% of shares outstanding voted.

Fifteen Form 4s on 11 September. Options cancelled for cash plus CVRs.

Apeiron's Schedule 13D/A reports zero AtaiBeckley shares as of 11 September. Mechanical: every holder went to zero at close, and the filing says nothing about where the cash went. The open question is whether the sector's most active European investor redeploys in Europe. No filing answers that yet, so we make no claim.

Definium: FDA Breakthrough Therapy designation for DT120 in major depressive disorder on 8 September, its second after GAD, on the Emerge data (8.1 point MADRS separation). Voyage's registry record now shows a primary completion date of 15 July 2026.

Lilly, brenipatide: CTIS now lists a sixth record, 2025-522640-41-00, a Phase 2 asthma study with 29 sites across France (10), Germany (9), the Netherlands (6) and Poland (4), recruiting since February. It was not in our August set. France and the Netherlands are new countries in the compound's disclosed CTIS footprint. The alcohol use disorder Phase 3 record was republished on 11 September, member states and sites unchanged.

GH Research: 6-K for investor meetings 14 to 16 September, director option grant 9 September. Compass: zero SEC filings, two Companies House share allotment forms for August.

---

Europe: checked, nothing new

CTIS, sixteen search terms: no new psychedelic authorisation since 8 September. ClinicalTrials.gov, psilocybin, MDMA, LSD, ketamine and esketamine: no record with an EU site updated since 8 September outside anaesthesia. BfArM compassionate use table: psilocybin at ZI Mannheim to 17 June 2027, academic sponsor, no MDMA entry, unchanged. CHMP September agenda: the only ketamine item is a paediatric sufentanil and ketamine combination. NICE guidance search: nothing. CORDIS: no new grant signed.

---

Failed checks, not zeros

BfArM press pages returned 404, EMA site search 401, NICE guidance in development 403, Zorginstituut API 500, AtaiBeckley and Lilly investor pages unreachable. A failed check is a gap in our coverage, not evidence of absence.

---

Ledger

Issue 4, scored: hit. The rule, pinned in Issue 10 before Panorama reported: raw placebo adjusted HAM-A at week 12 under 5.4 points is a hit, at or above 5.4 a miss. Panorama came in at 5.1. Voyage was 5.4.

The margin is 0.3 points. The rule was binary, a 0.3 point miss would have been scored as a miss, so this is scored as a hit and nothing more. The thesis was that Panorama's 50 µg arm, built to stop patients guessing their assignment, would compress the signal. Both arms came down against Voyage: drug 9.8 against 11.6, placebo 4.7 against 6.2. The raw gap narrowed by 0.3 points. The standardised effect size fell from 0.81 to 0.64, which is not the pinned metric and does not score, but it is the number the thesis predicted.

Issue 12, unchanged. The rule was pinned to five named CTIS records. A sixth exists. The footprint grew and the call stays exactly as written. That is why the rule named records instead of counting them.

Issue 7, date fixed. Twelve months after close is 11 September 2027.

Thirteen calls. Two resolved, eleven open, zero falsified. Every call, its rule and its status, on the ledger page at psychedelicbrief.com.

Correction, 15 Sept: the email version gave 29 sites across three countries. The CTIS record lists France 10, Germany 9, the Netherlands 6 and Poland 4.

---

The call

Lilly does not name BPL-003, VLS-01 or mebufotenin in its Q3 2026 earnings press release, earnings deck, prepared remarks or Q&A, as published on the day of the release.

Resolves that day, late October. Falsifier: any of the three names in any of the four documents, pipeline chart included. "AtaiBeckley" alone does not count. Scored in the issue after the release.

Why this call: if the compounds are worth naming to Lilly's shareholders, they are a pipeline priority. If not, Europe is waiting on a rounding error.

The first positive Phase 3 in this class ran on European patients. Whether European patients get the drug is a question no filing has answered. That gap is why we publish.